Regeneron Pharmaceuticals
(REGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 14,342,900 | 14,202,000 | 13,117,200 | 12,172,900 | 16,071,700 |
| Cost of Goods | 2,100,700 | 1,970,500 | 1,815,800 | 1,560,400 | 2,437,500 |
| Gross Profit | 12,242,200 | 12,231,500 | 11,301,400 | 10,612,500 | 13,634,200 |
| Operating Expenses | 8,665,000 | 8,241,300 | 7,255,101 | 5,874,000 | 4,687,900 |
| Operating Income | 3,577,900 | 3,990,700 | 4,047,100 | 4,738,900 | 8,946,800 |
| Interest Expense | 43,800 | 55,200 | 73,000 | 59,400 | 57,300 |
| Other Income | 1,696,600 | 844,400 | 225,200 | 179,300 | 436,300 |
| Pre-tax Income | 5,230,700 | 4,779,900 | 4,199,300 | 4,858,800 | 9,325,800 |
| Income Tax | 725,800 | 367,300 | 245,700 | 520,400 | 1,250,500 |
| Net Income Continuous | 4,504,900 | 4,412,600 | 3,953,600 | 4,338,400 | 8,075,300 |
| Net Income | $4,504,900 | $4,412,600 | $3,953,600 | $4,338,400 | $8,075,300 |
| EPS Basic Total Ops | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 |
| EPS Basic Continuous Ops | 43.07 | 40.90 | 37.05 | 40.51 | 76.40 |
| EPS Diluted Total Ops | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 |
| EPS Diluted Continuous Ops | 41.48 | 38.34 | 34.77 | 38.22 | 71.97 |
| EPS Diluted Before Non-Recurring Items | 35.51 | 38.62 | 37.66 | 40.11 | 74.66 |
| EBITDA(a) | $4,121,601 | $4,473,599 | $4,468,100 | $5,080,300 | $9,233,001 |